Jeroen Tonnar appointed chief business officer at Cristal Therapeutics

21 April 2015

Dutch privately-held life sciences company Cristal Therapeutics has appointed Jeroen Tonnar as new chief business officer responsible for business development, partnering and licensing activities.

He joined Organon as a neuroscientist in 1982 and from there held further positions at the company, before moving to Schering-Plough where he was head of discovery collaborations for Europe. After Schering-Plough was acquired by Merck & Co (NYSE: MRK), he joined its worldwide licensing organization in February 2010.

Joost Holtuis, chief executive of Cristal, said: "I am delighted to welcome Jeroen to Cristal Therapeutics and look forward to working with him. Jeroen will strengthen our key existing business relationships and focus on finding, executing and fostering new partnering opportunities for Cristal Therapeutics."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK